23-10-2014 10:05 CEST Bristol-Myers Squibb

14-10-2014 14:08 CEST Bristol-Myers Squibb

29-09-2014 09:17 CEST Bristol-Myers Squibb

26-09-2014 16:49 CEST Gilead Gilead Sciences, Inc. (Nasdaq: GILD) kunngjorde i dag at Komitéen for legemidler til mennesker (CHMP), tilknyttet EUs legemiddeltilsyn, har kommet med en positiv uttalelse vedrørende selskapets søknad om markedsføringstillatelse (MAA) for Harvoni ®.

Bristol-Myers Squibb får positiv CHMP-vurdering for Daklinza® (daclatasvir) for behandling av kronisk hepatitt C i EU

30-06-2014 14:00 CEST Bristol-Myers Squibb

02-06-2014 14:00 CEST Bristol-Myers Squibb

 In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)

16-05-2014 10:17 CEST Bristol-Myers Squibb

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b                                             Non-Small Cell Lung Cancer Trials

16-05-2014 10:13 CEST Bristol-Myers Squibb

Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b Study

16-05-2014 09:48 CEST Bristol-Myers Squibb • Across doses (n=107), 48% and 41% of this heavily pre-treated patient population that received nivolumab as a single agent was alive at two and three years, respectively • Spectrum, frequency and severity of treatment-related adverse events from this study were consistent with those initially reported for these patients in prior publications

Bristol- Myers Squibb presenterer data for et legemiddel i perorale kombinasjoner på tvers av ulike genotyper av hepatitt C på The International Liver Congress

24-03-2014 15:46 CET Bristol-Myers Squibb